Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Alterations in folate-dependent one-carbon metabolism as colon cell transition from normal to cancerous.

Asante I, Chui D, Pei H, Zhou E, De Giovanni C, Conti D, Louie S.

J Nutr Biochem. 2019 Jul;69:1-9. doi: 10.1016/j.jnutbio.2019.02.008. Epub 2019 Mar 12.

PMID:
31035100
2.

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R.

De Giovanni C, Landuzzi L, Palladini A, Ianzano ML, Nicoletti G, Ruzzi F, Amici A, Croci S, Nanni P, Lollini PL.

Cancers (Basel). 2019 Apr 11;11(4). pii: E517. doi: 10.3390/cancers11040517.

3.

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis.

De Giovanni C, Nanni P, Landuzzi L, Ianzano ML, Nicoletti G, Croci S, Palladini A, Lollini PL.

BMC Cancer. 2019 Feb 7;19(1):126. doi: 10.1186/s12885-019-5339-4.

4.

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis.

Nanni P, De Giovanni C, Burocchi A, Nicoletti G, Landuzzi L, Palladini A, Ianzano ML, Arioli I, Colombo MP, Lollini PL.

Oncoimmunology. 2018 Jun 11;7(8):e1465164. doi: 10.1080/2162402X.2018.1465164. eCollection 2018.

5.

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.

Palladini A, Nicoletti G, Lamolinara A, Dall'Ora M, Balboni T, Ianzano ML, Laranga R, Landuzzi L, Giusti V, Ceccarelli C, Santini D, Taffurelli M, Di Oto E, Asioli S, Amici A, Pupa SM, De Giovanni C, Tagliabue E, Iezzi M, Nanni P, Lollini PL.

Oncotarget. 2017 Apr 13;8(33):54444-54458. doi: 10.18632/oncotarget.17088. eCollection 2017 Aug 15.

6.

A Distinct Genetic Cluster in Cultivated Chickpea as Revealed by Genome-wide Marker Discovery and Genotyping.

Pavan S, Lotti C, Marcotrigiano AR, Mazzeo R, Bardaro N, Bracuto V, Ricciardi F, Taranto F, D'Agostino N, Schiavulli A, De Giovanni C, Montemurro C, Sonnante G, Ricciardi L.

Plant Genome. 2017 Jul;10(2). doi: 10.3835/plantgenome2016.11.0115.

7.

Genetic variation of a global germplasm collection of chickpea (Cicer arietinum L.) including Italian accessions at risk of genetic erosion.

De Giovanni C, Pavan S, Taranto F, Di Rienzo V, Miazzi MM, Marcotrigiano AR, Mangini G, Montemurro C, Ricciardi L, Lotti C.

Physiol Mol Biol Plants. 2017 Jan;23(1):197-205. doi: 10.1007/s12298-016-0397-4. Epub 2016 Dec 19.

8.

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.

Croci S, Nanni P, Palladini A, Nicoletti G, Grosso V, Benegiamo G, Landuzzi L, Lamolinara A, Ianzano ML, Ranieri D, Dall'Ora M, Iezzi M, De Giovanni C, Lollini PL.

Breast Cancer Res. 2015 May 22;17:70. doi: 10.1186/s13058-015-0588-x.

9.

Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas.

Landuzzi L, Ianzano ML, Nicoletti G, Palladini A, Grosso V, Ranieri D, Dall'Ora M, Raschi E, Laranga R, Gambarotti M, Picci P, De Giovanni C, Nanni P, Lollini PL.

Oncotarget. 2014 Dec 15;5(23):11924-38.

10.

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.

De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Ianzano ML, Dall'Ora M, Grosso V, Ranieri D, Laranga R, Croci S, Amici A, Penichet ML, Iezzi M, Cavallo F, Nanni P, Lollini PL.

Breast Cancer Res. 2014 Jan 23;16(1):R10. doi: 10.1186/bcr3602.

11.

Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.

Ianzano ML, Croci S, Nicoletti G, Palladini A, Landuzzi L, Grosso V, Ranieri D, Dall'Ora M, Santeramo I, Urbini M, De Giovanni C, Lollini PL, Nanni P.

Oncotarget. 2014 Jan 15;5(1):108-19.

12.

Preclinical vaccines against mammary carcinoma.

Lollini PL, Cavallo F, De Giovanni C, Nanni P.

Expert Rev Vaccines. 2013 Dec;12(12):1449-63. doi: 10.1586/14760584.2013.845530. Review.

13.

Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment.

Iommarini L, Kurelac I, Capristo M, Calvaruso MA, Giorgio V, Bergamini C, Ghelli A, Nanni P, De Giovanni C, Carelli V, Fato R, Lollini PL, Rugolo M, Gasparre G, Porcelli AM.

Hum Mol Genet. 2014 Mar 15;23(6):1453-66. doi: 10.1093/hmg/ddt533. Epub 2013 Oct 24.

PMID:
24163135
14.

Preclinical HER-2 Vaccines: From Rodent to Human HER-2.

Lollini PL, De Giovanni C, Nanni P.

Front Oncol. 2013 Jun 10;3:151. doi: 10.3389/fonc.2013.00151. eCollection 2013.

15.

Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.

Nanni P, Gatta V, Menotti L, De Giovanni C, Ianzano M, Palladini A, Grosso V, Dall'ora M, Croci S, Nicoletti G, Landuzzi L, Iezzi M, Campadelli-Fiume G, Lollini PL.

PLoS Pathog. 2013 Jan;9(1):e1003155. doi: 10.1371/journal.ppat.1003155. Epub 2013 Jan 31.

16.

Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.

De Giovanni C, Nicoletti G, Landuzzi L, Romani F, Croci S, Palladini A, Murgo A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Iezzi M, Stramucci L, Barbieri E, Lemoli RM, Nanni P, Lollini PL.

Br J Cancer. 2012 Oct 9;107(8):1302-9. doi: 10.1038/bjc.2012.394. Epub 2012 Aug 28.

17.

Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor.

Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, Grosso V, Stivani V, Antognoli A, Lamolinara A, Landuzzi L, di Tomaso E, Iezzi M, De Giovanni C, Lollini PL.

PLoS One. 2012;7(6):e39626. doi: 10.1371/journal.pone.0039626. Epub 2012 Jun 21.

18.

Characterization of polygenic resistance to powdery mildew in tomato at cytological, biochemical and gene expression level.

Li C, Faino L, Dong L, Fan J, Kiss L, De Giovanni C, Lebeda A, Scott J, Matsuda Y, Toyoda H, Lindhout P, Visser RG, Bonnema G, Bai Y.

Mol Plant Pathol. 2012 Feb;13(2):148-59. doi: 10.1111/j.1364-3703.2011.00737.x. Epub 2011 Aug 22.

PMID:
21883866
19.

A mutation threshold distinguishes the antitumorigenic effects of the mitochondrial gene MTND1, an oncojanus function.

Gasparre G, Kurelac I, Capristo M, Iommarini L, Ghelli A, Ceccarelli C, Nicoletti G, Nanni P, De Giovanni C, Scotlandi K, Betts CM, Carelli V, Lollini PL, Romeo G, Rugolo M, Porcelli AM.

Cancer Res. 2011 Oct 1;71(19):6220-9. doi: 10.1158/0008-5472.CAN-11-1042. Epub 2011 Aug 18.

20.

The molecular basis of herpesviruses as oncolytic agents.

Menotti L, Campadelli-Fiume G, Nanni P, Lollini PL, De Giovanni C.

Curr Pharm Biotechnol. 2012 Jul;13(9):1795-803. Review.

PMID:
21740356
21.

Rethinking herpes simplex virus: the way to oncolytic agents.

Campadelli-Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini PL, Menotti L.

Rev Med Virol. 2011 Jul;21(4):213-26. doi: 10.1002/rmv.691. Epub 2011 May 27. Review.

PMID:
21626603
22.

HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines.

Landuzzi L, Antognoli A, Nicoletti G, Croci S, Palladini A, Ianzano ML, Murgo A, Stivani V, Grosso V, Nanni P, De Giovanni C, Lollini PL.

Vaccine. 2011 Jun 24;29(29-30):4690-7. doi: 10.1016/j.vaccine.2011.04.096. Epub 2011 May 11.

PMID:
21569812
23.

2011: the immune hallmarks of cancer.

Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL.

Cancer Immunol Immunother. 2011 Mar;60(3):319-26. doi: 10.1007/s00262-010-0968-0. Epub 2011 Jan 26.

24.

Vaccines and other immunological approaches for cancer immunoprevention.

Lollini PL, Nicoletti G, Landuzzi L, Cavallo F, Forni G, De Giovanni C, Nanni P.

Curr Drug Targets. 2011 Dec;12(13):1957-73. Review.

PMID:
21158706
25.

Immunoprevention and immunotherapy of mammary carcinoma.

Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Nanni P.

Breast J. 2010 Sep-Oct;16 Suppl 1:S39-41. doi: 10.1111/j.1524-4741.2010.01002.x.

PMID:
21050308
26.

Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.

Croci S, Recktenwald CV, Lichtenfels R, Nicoletti G, Dressler SP, De Giovanni C, Astolfi A, Palladini A, Shin-ya K, Landuzzi L, Nanni P, Lollini PL, Seliger B.

Proteomics. 2010 Nov;10(21):3835-53. doi: 10.1002/pmic.200900643.

PMID:
20957756
27.

In silico modeling and in vivo efficacy of cancer-preventive vaccinations.

Palladini A, Nicoletti G, Pappalardo F, Murgo A, Grosso V, Stivani V, Ianzano ML, Antognoli A, Croci S, Landuzzi L, De Giovanni C, Nanni P, Motta S, Lollini PL.

Cancer Res. 2010 Oct 15;70(20):7755-63. doi: 10.1158/0008-5472.CAN-10-0701. Epub 2010 Oct 5.

28.

Evidences for insulator activity of the 5'UTR of the Drosophila melanogaster LTR-retrotransposon ZAM.

Minervini CF, Ruggieri S, Traversa M, D'Aiuto L, Marsano RM, Leronni D, Centomani I, De Giovanni C, Viggiano L.

Mol Genet Genomics. 2010 May;283(5):503-9. doi: 10.1007/s00438-010-0529-4. Epub 2010 Apr 3.

PMID:
20364351
29.

A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins.

Quaglino E, Mastini C, Amici A, Marchini C, Iezzi M, Lanzardo S, De Giovanni C, Montani M, Lollini PL, Masucci G, Forni G, Cavallo F.

Cancer Res. 2010 Apr 1;70(7):2604-12. doi: 10.1158/0008-5472.CAN-09-2548. Epub 2010 Mar 23.

30.

High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.

Nanni P, Nicoletti G, Landuzzi L, Croci S, Murgo A, Palladini A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Maira SM, García-Echeverría C, Scotlandi K, De Giovanni C, Lollini PL.

Eur J Cancer. 2010 Feb;46(3):659-68. doi: 10.1016/j.ejca.2009.11.018. Epub 2009 Dec 22.

PMID:
20031388
31.

Molecular and cellular biology of rhabdomyosarcoma.

De Giovanni C, Landuzzi L, Nicoletti G, Lollini PL, Nanni P.

Future Oncol. 2009 Nov;5(9):1449-75. doi: 10.2217/fon.09.97. Review.

PMID:
19903072
32.

Oncolytic herpes virus retargeted to HER-2.

Lollini PL, Menotti L, De Giovanni C, Campadelli-Fiume G, Nanni P.

Cell Cycle. 2009 Sep 15;8(18):2859-60. Epub 2009 Sep 26. No abstract available.

PMID:
19729994
33.

APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the Apc(Min) mouse model in vivo.

Sale S, Fong IL, de Giovanni C, Landuzzi L, Brown K, Steward WP, Gescher AJ.

Eur J Cancer. 2009 Nov;45(16):2731-5. doi: 10.1016/j.ejca.2009.07.004. Epub 2009 Aug 18.

PMID:
19695862
34.

Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.

Menotti L, Nicoletti G, Gatta V, Croci S, Landuzzi L, De Giovanni C, Nanni P, Lollini PL, Campadelli-Fiume G.

Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9039-44. doi: 10.1073/pnas.0812268106. Epub 2009 May 20.

35.

Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy.

De Giovanni C, Nicoletti G, Landuzzi L, Croci S, Palladini A, Antognoli A, Murgo A, Ianzano ML, Grosso V, Stivani V, Iezzi M, Musiani P, Nanni P, Lollini PL.

Vaccine. 2009 Mar 23;27(14):2065-9. doi: 10.1016/j.vaccine.2009.01.113. Epub 2009 Jan 31.

PMID:
19428831
36.

Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4.

Nanni P, Nicoletti G, Palladini A, Astolfi A, Rinella P, Croci S, Landuzzi L, Monduzzi G, Stivani V, Antognoli A, Murgo A, Ianzano M, De Giovanni C, Lollini PL.

Mol Cancer Ther. 2009 Apr;8(4):754-61. doi: 10.1158/1535-7163.MCT-08-0678.

37.

Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE.

Misra S, Hascall VC, De Giovanni C, Markwald RR, Ghatak S.

J Biol Chem. 2009 May 1;284(18):12432-46. doi: 10.1074/jbc.M806772200. Epub 2009 Feb 26.

38.

A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome.

De Giovanni C, Nicoletti G, Palladini A, Croci S, Landuzzi L, Antognoli A, Murgo A, Astolfi A, Ferrini S, Fabbi M, Orengo AM, Amici A, Penichet ML, Aurisicchio L, Iezzi M, Musiani P, Nanni P, Lollini PL.

Hum Gene Ther. 2009 May;20(5):453-64. doi: 10.1089/hum.2008.172.

PMID:
19215191
39.

Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis.

Croci S, Landuzzi L, Nicoletti G, Palladini A, Antognoli A, De Giovanni C, Nanni P, Lollini PL.

Pathol Oncol Res. 2007;13(4):336-9. Epub 2007 Dec 25.

40.

Naturally occurring broad-spectrum powdery mildew resistance in a Central American tomato accession is caused by loss of mlo function.

Bai Y, Pavan S, Zheng Z, Zappel NF, Reinstädler A, Lotti C, De Giovanni C, Ricciardi L, Lindhout P, Visser R, Theres K, Panstruga R.

Mol Plant Microbe Interact. 2008 Jan;21(1):30-9.

41.

Antimetastatic activity of a preventive cancer vaccine.

Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Antognoli A, Landuzzi L, Fabbi M, Ferrini S, Musiani P, Iezzi M, De Giovanni C, Lollini PL.

Cancer Res. 2007 Nov 15;67(22):11037-44. Erratum in: Cancer Res. 2007 Dec 15;67(24):12034.

42.

Response of tomato and its wild relatives in the genus Solanum to cucumber mosaic virus and satellite RNA combinations.

Cillo F, Pasciuto MM, De Giovanni C, Finetti-Sialer MM, Ricciardi L, Gallitelli D.

J Gen Virol. 2007 Nov;88(Pt 11):3166-76.

PMID:
17947544
43.

Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells.

Croci S, Nicoletti G, Landuzzi L, Palladini A, Chiarini F, Nanni P, Lollini PL, De Giovanni C.

Oncol Rep. 2007 Aug;18(2):451-6.

PMID:
17611670
44.

Inhibition of prostate carcinogenesis by combined active immunoprophylaxis.

De Giovanni C, Croci S, Nicoletti G, Landuzzi L, Palladini A, Pannellini T, Borgia L, Iezzi M, Di Carlo E, Orengo AM, Kennedy RC, Lollini PL, Nanni P, Musiani P.

Int J Cancer. 2007 Jul 1;121(1):88-94.

45.

Cancer immunoprevention.

Lollini PL, De Giovanni C, Pannellini T, Cavallo F, Forni G, Nanni P.

Future Oncol. 2005 Feb;1(1):57-66. Review.

PMID:
16555976
46.

Endothelin-3 production by human rhabdomyosarcoma: a possible new marker with a paracrine role.

Palladini A, Astolfi A, Croci S, De Giovanni C, Nicoletti G, Rosolen A, Sartori F, Lollini PL, Landuzzi L, Nanni P.

Eur J Cancer. 2006 Mar;42(5):680-7. Epub 2006 Jan 24.

PMID:
16439111
47.

New target antigens for cancer immunoprevention.

Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Nanni P.

Curr Cancer Drug Targets. 2005 May;5(3):221-8. Review.

PMID:
15892621
48.

A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice.

Lo Iacono M, Cavallo F, Quaglino E, Rolla S, Iezzi M, Pupa SM, De Giovanni C, Lollini PL, Musiani P, Forni G, Calogero RA.

Int J Immunopathol Pharmacol. 2005 Apr-Jun;18(2):351-63.

PMID:
15888257
49.

Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.

Astolfi A, Landuzzi L, Nicoletti G, De Giovanni C, Croci S, Palladini A, Ferrini S, Iezzi M, Musiani P, Cavallo F, Forni G, Nanni P, Lollini PL.

Am J Pathol. 2005 Apr;166(4):1205-16.

50.

Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario.

Astolfi A, Rolla S, Nanni P, Quaglino E, De Giovanni C, Iezzi M, Musiani P, Forni G, Lollini PL, Cavallo F, Calogero RA.

Cancer Immunol Immunother. 2005 Jun;54(6):599-610. Epub 2005 Feb 3.

PMID:
15690207

Supplemental Content

Loading ...
Support Center